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Abstract Esophageal cancer is a deadly cancer with
esophageal squamous cell carcinoma (ESCC) as the major
type. Until now there has been a lack of reliable prognostic
markers for this malignancy. This study aims to investigate
the clinical correlation between Forkhead box M1 (FoxM1)
and patients’ parameters in ESCC.
Methods Immunohistochemistry was performed to inves-
tigate the expression and localization of FoxM1 in 64
ESCC tissues and 10 nontumor esophageal tissues ran-
domly selected from 64 patients before these data were
used for clinical correlations.
Results Cytoplasmic and nuclear expressions of FoxM1
were found in 63 and 16 of the 64 ESCC tissues, respec-
tively. Low cytoplasmic expression of FoxM1 was corre-
lated with early pathological stage in ESCC (P = 0.018),
while patients with nuclear FoxM1 were younger in age
than those without nuclear expression (P \ 0.001).
Upregulation of FoxM1 mRNA was found in five ESCC
cell lines (HKESC-1, HKESC-2, HKESC-3, HKESC-4,
and SLMT-1) when compared to non-neoplastic esopha-
geal squamous cell line NE-1 using quantitative polymer-
ase chain reaction (qPCR). Except for HKESC-3, all
studied ESCC cell lines demonstrated a high expression of
FoxM1 protein using immunoblot. A high mRNA level of
FoxM1 was observed in all of the ESCC tissues examined
when compared to their adjacent nontumor tissues using
qPCR.
Conclusion Cytoplasmic FoxM1 was correlated with
pathological stage and might be a biomarker for advanced
ESCC.
Introduction
Forkhead box M1 (FoxM1) is a member of the Forkhead
transcription factor family, which is evolutionarily con-
served and is defined by having a common DNA-binding
domain called Forkhead or winged-helix domain [1]. The
FOXM1 gene is located on chromosome 12 12p13.3 [2]. It
is involved in an array of biological processes, including
metabolism and development, cell proliferation, apoptosis
and invasion, longevity, and cancer [3]. FoxM1 has high
expression in fetal tissues with active cell proliferation and
its expression is negligible in differentiated cells [4]. It
regulates the cell cycle by modulating the transcription of
various cell cycle-related genes essential for G1-S and
G2-M progression, chromosome stability, and segregation,
including p27kip1, cyclin B1, and cyclin D [5–8]. Recently,
FoxM1 has been linked to tumorigenesis and progression of
certain cancers. Recurrent DNA copy number alterations
(CNA) were reported in an array-based comparative
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genome hybridization study of malignant peripheral nerve
sheath tumor (MPNST). This gain/loss in copy number of
FOXM1 is associated with survival in MPNST [2].
Upregulation of FoxM1 expression is found in basal cell
carcinomas [9], glioblastomas [10], non-small-cell lung
cancers [11], and breast cancers [12, 13]. Mice with FoxM1
conditionally deleted from hepatocytes were highly resis-
tant to liver tumor induction by phenobarbital and diet-
hylnitrosamine [14]. Moreover, expression of the FoxM1
transgene in mice increased with the size of the colorectal
tumors while conditional FoxM1 knockout mice showed
reduced growth of colorectal tumors [6]. These results
suggest a role for FoxM1 in tumor initiation and progres-
sion [4]. To our knowledge, no study has investigated the
clinical significance of FoxM1 in esophageal squamous
cell carcinoma (ESCC), which is a major type of esopha-
geal cancer [15]. The aim of this present study was to
investigate the prognostic significance of FoxM1 in ESCC.
Materials and methods
Human esophageal cell lines
Five human ESCC cell lines, HKESC-1, HKESC-2,
HKESC-3, HKESC-4 and SLMT-1, and one human non-
neoplastic esophageal squamous cell line, NE-1, were used
in this study. These cell lines were previously established
by our team [16–20]. NE-1 cells were cultured in kerati-
nocyte-SFM medium supplemented with bovine pituitary
extract and human recombinant epidermal growth factor
(Invitrogen, Carlsbad, CA). HKESC-1 and HKESC-4 cells
were maintained in Minimum Essential Medium (MEM)
medium (Invitrogen) with 10% heat-inactivated fetal
bovine serum (FBS) (Invitrogen) and 1% penicillin and
streptomycin (P/S) (Invitrogen). HKESC-2, HKESC-3, and
SLMT-1 cells were cultured in MEM medium with 20%
FBS and 1% P/S. All cell lines were maintained in a
humidified atmosphere at 37C containing 5% CO2.
Patients and clinical specimens
We recruited 64 ESCC patients who had undergone
esophagectomy between 1997 and 2005 at the Department
of Surgery, Queen Mary Hospital, Hong Kong. Consent to
use clinical specimens for this study was obtained from the
Institutional Review Board of The University of Hong
Kong/Hospital Authority Hong Kong West Cluster (HKU/
HA HKW IRB). There were 47 men and 17 women and the
mean age was 64.6 years (range = 40–87 years). None of
the patients had received neoadjuvant chemotherapy or
radiotherapy before esophagectomy. Data of patient
demographics, histopathology, and long-term follow-up
were captured in a prospectively collected database.
Specimens of primary tumor and nontumor tissues obtained
from near the proximal resection margins were stored at
–80C and retained for laboratory studies and subsequent
analyses. The site and size of the tumors were recorded.
Standard tissue blocks were prepared by fixing the speci-
mens in 10% formalin before embedding in paraffin wax.
Five-micron sections were prepared and stained with
hematoxylin and eosin for light microscopy. Stained sec-
tions were reviewed and tumors were graded according to
the criteria of the World Health Organization (WHO).
Cancers were staged according to TNM classification.
Reverse transcription (RT) and quantitative polymerase
chain reaction (qPCR)
The expression of FoxM1 mRNA in esophageal cell lines
and clinical specimens was determined using qPCR. RNA
was extracted using TRIzol reagent (Invitrogen), according
to manufacturer’s instructions. RT and qPCR were per-
formed as described [21, 22]. Five hundred nanograms
of RNA was reverse-transcribed into cDNA using the
SuperScript III First-Strand Synthesis System for RT-PCR
kit (Invitrogen), following the manufacturer’s protocol.
cDNA (0.3 and 0.6 lg) from cultured cells and tissues was
used for qPCR using Platinum Quantitative PCR Super-
Mix-UDG w/ROX (Invitrogen) and FoxM1-specific prim-
ers (forward: 50-ACC CAA ACC AGC TAT GAT GC-30
and reverse: 50-GAA GCC ACT GGA TGT TGG AT-30).
b-Actin was used as an internal control in a parallel
experiment, using its specific primers (forward: 50-CCA
TCA TGA AGT GTG ACG TG-30 and reverse: 50-ATC
CAC ATC TGC TGG AAG GT-30). qPCR was performed
using an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems, Carlsbad, CA). Each sample was
performed in at least duplicates.
Immunoblot
The protein level of FoxM1 in esophageal cell lines was
detected using immunoblot as described [23, 24]. Briefly,
cultured cells were washed twice with ice-cold 1 9 phos-
phate-buffered saline (PBS, pH 7.4). Ice-cold cell lysis
buffer (Cell Signaling Technology, Danvers, MA) was
added to cell monolayers to extract proteins by scraping. Cell
lysates were left on ice for 15 min before being centrifuged at
13,200 rpm for 15 min at 4C. Protein concentration was
estimated using Bradford Protein Assay solution (Bio-Rad,
Hercules, CA). Following the addition of 6 9 sample buffer
to the cell lysates, 25 lg of protein was resolved onto an 8%
sodium dodecyl sulfate (SDS) polyacrylamide gel at room
temperature before the transfer of proteins onto the polyvi-
nylidene fluoride (PVDF) membrane for 2.5 h at 4C. After
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blocking with 5% skimmed milk in Tris-buffered saline with
Tween-20 (TBST) at room temperature for 2 h, membranes
were probed with polyclonal rabbit anti-FoxM1 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1,500
overnight at 4C. Monoclonal mouse anti-b-actin antibody
(Sigma-Aldrich, St Louis, MO) at 1:10,000 was used as a
loading control. After washing with TBST, membranes were
incubated with either goat anti-rabbit (Zymed, Carlsbad,
CA) (1:7,000 for detecting anti-FoxM1 antibody) or goat
anti-mouse (Zymed) (1:20,000 for detecting anti-b-actin
antibody) secondary antibodies conjugated with horseradish
peroxidase (HRP) for 1 h at room temperature. Following
washing with TBST, signals were visualized using ECL Plus
Western blotting reagent pack (GE Healthcare Biosciences,
Piscataway, NJ). The apparent molecular weight of FoxM1
and b-actin on gels was 100 and 42 kDa, respectively.
Immunohistochemistry
Five-micron sections from tumors and nontumor tissues
were prepared and mounted on glass slides for immuno-
histochemistry as previously described [23, 25, 26]. Sec-
tions were deparaffinized and rehydrated. Antigen retrieval
was performed by heating sections in 0.1 M citrus buffer
(pH 6.0) in a microwave for 10 min. Endogenous peroxi-
dase activities were blocked by incubating sections with
3% hydrogen peroxide at room temperature for 20 min.
After washing with TBS (pH 7.6), nonspecific binding sites
were blocked with 10% normal goat serum (Dako, Glost-
rup, Denmark) in TBST at room temperature for 1 h.
Sections were incubated with anti-FoxM1 antibody at
1:600 overnight at 4C. After washing with TBS, sections
were incubated with anti-rabbit-labeled polymer-HRP
provided in EnVision ? System-HRP (Dako) at room
temperature for 45 min to detect the primary antibody.
Signals were visualized by incubating sections with liquid
DAB ? (diaminobenzidine) (Dako) before counterstaining
with hematoxylin. A colorectal carcinoma section from the
tissue microarray was used as a positive control (Fig. 1a),
while normal goat serum as a substitution for anti-FoxM1
antibody was used as a negative control (Fig. 1b). Stained
sections were examined by Dr. Chan under light micro-
scope. The expression of cytoplasmic FoxM1 was evalu-
ated according to the methodology of Liu et al. [10] with
modifications. The expression of FoxM1 was categorized
according to the percentage of cancer cells stained positive
with anti-FoxM1 antibody (score from 0 to 3, where
0 B 5%, 1 = 6–25%, 2 = 26–50%, and 3 C 51%) and the
intensities of the immunostain (1 ? , 2 ? , 3 ?). A
weighted index score (0–9) was calculated for each section
by multiplying the values of these two categories. For
example, the weighted index score should be 6 if 30% of
cancer cells were stained (score = 2) with strong signals
(score = 3). For cytoplasmic FoxM1 expression, tumors
were further grouped into a low-expression group
(weighted index score = 0–4) and a high-expression group
(weighted index score = 5–9). For nuclear FoxM1, its
expression segregated the tumors into an ‘‘absence’’ group
or a ‘‘presence’’ group.
Statistical analysis
Data are expressed as mean ± SEM. Pearson’s v2 test was
used to assess the correlations between immunohisto-
chemical data and categorical clinicopathological charac-
teristics. The Kaplan-Meier method was used for survival
analysis, and the differences in survival were estimated
using the log-rank test. A P value of less than 0.05 was
considered statistically significant. All statistical analyses
were performed using SPSS 12.0 for Windows (SPSS, Inc.,
Chicago, IL).
Fig. 1 Immunohistochemical staining of FoxM1 in tissue microarray of colorectal cancers. Anti-FoxM1 antibody was used to stain FoxM1 in
colorectal cancer tissues from tissue microarray (a). A negative control was included in a parallel experiment (b). Original magnification, 2009
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Results
High mRNA level of FoxM1 in ESCC cell lines
and tissues
A high level of FoxM1 mRNA was found in ESCC cell
lines compared to that in the non-neoplastic squamous cell
line NE-1 using qPCR. An increase of 24.34-, 57.45-,
103.72-, 25.81-, and 13.92-fold in the mRNA level of
FoxM1 was observed in HKESC-1, HKESC-2, HKESC-3,
HKESC-4, and SLMT-1 cells, respectively, compared to
that in NE-1 cells (Fig. 2). All of ten ESCC tissues studied
showed an increase in FoxM1 mRNA when compared to
their corresponding nontumor counterparts. The upregula-
tion of FoxM1 ranged from about 3- (patient 9) to 500-fold
(patient 6) (Fig. 3).
High protein level of FoxM1 in ESCC cell lines
The protein level of FoxM1 in cultured cells was analyzed
using immunoblot. Non-neoplastic NE-1 cells expressed an
undetectable protein level of FoxM1. Except HKESC-3
cells, ESCC cells, including HKESC-1, HKESC-2,
HKESC-4, and SLMT-1, showed an elevated protein level
of FoxM1 compared to NE-1 cells (Fig. 4).
Low expression of cytoplasmic FoxM1 associated
with early-stage ESCC
Immunohistochemistry was performed to investigate the
expression and localization of FoxM1 in 64 ESCC tissues
and 10 randomly selected nontumor tissues from the same
patient cohort. Cytoplasmic expression of FoxM1 was
found in 98.44% (63/64) of ESCC tissues (Fig. 5), while its
nuclear expression was observed in 25% (16/64) of ESCC
Fig. 2 High mRNA level of FoxM1 in ESCC cell lines. qPCR was
performed to investigate the mRNA level of FoxM1 in ESCC cell
lines (HKESC-1, HKESC-2, HKESC-3, HKESC-4, and SLMT-1) and
the non-neoplastic esophageal cell line NE-1. High mRNA level of
FoxM1 was associated with ESCC cells. Each sample was repeated at
least in duplicate
Fig. 3 High mRNA level of FoxM1 in ESCC tissues. qPCR was
performed to investigate the mRNA level of FoxM1 in ten pairs of
ESCC tissues and their adjacent nontumor tissues. High expression of
FoxM1 mRNA was found in all of the ESCC cases. The expression of
FoxM1 in nontumor tissues was arbitrarily set to 1. Each sample was
repeated at least in duplicate
Fig. 4 High protein level of FoxM1 in ESCC cell lines. Immunoblot
was performed to examine the protein level of FoxM1 in ESCC cell
lines (HKESC-1/HK-1, HKESC-2/HK-2, HKESC-3/HK-3, HKESC-
4/HK-4, and SLMT-1) and non-neoplastic esophageal cell line NE-1.
High protein level of FoxM1 was associated with most ESCC cell
lines, except HK-3
Fig. 5 Cytoplasmic localization of FoxM1 in ESCC tissues. Immu-
nohistochemistry was used to study the expression and localization of
FoxM1 in ESCC tissues and most cases of ESCC tissues had
cytoplasmic staining of FoxM1. Original magnification, 2009
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tissues (Fig. 6). All nontumor tissues were positive for
cytoplasmic FoxM1, whereas 20% (2/10) of them expres-
sed nuclear FoxM1. Specifically, FoxM1 expression was
found mainly in the proliferating layer of the non-neo-
plastic epithelium and the expression was relatively low in
the more differentiated layer (Fig. 7).
Patients with lower expression of cytoplasmic FoxM1
were more likely in the early stage of ESCC (P = 0.018)
than those with higher expression (19/37, 51.4% vs. 6/27,
22.2%, respectively) (Table 1). No significant difference in
survival after surgery could be found between patients with
low expression of cytoplasmic FoxM1 and those with high
expression (14.75 vs. 23.28 months, respectively, P =
0.977) (Fig. 8). Patients with nuclear expression of FoxM1
were younger than those without nuclear FoxM1 (57 vs.
67.13 years, P \ 0.001) (Table 2). The median postoper-
ative survival for patients with nuclear FoxM1 was similar
to those without (14.75 vs. 25.64 months, P = 0.697)
(Fig. 9).
Discussion
This study used immunohistochemistry to study the cor-
relations between FoxM1 and various clinicopathological
parameters in ESCC patients. Our data show that cyto-
plasmic FoxM1 is associated with pathological disease
stage. This is consistent with the report by Liu et al. [10],
which demonstrated that the expression of FoxM1 was
higher in patients with high-grade glioma. Another
study conducted by Chan et al. [27] also reported that
a higher FoxM1 level was significantly associated with
Fig. 6 Nuclear localization of FoxM1 in ESCC tissues. Immunohis-
tochemistry was used to reveal the expression and localization of
FoxM1 in ESCC tissues and about 25% of ESCC cases had tumors
with nuclear FoxM1. Original magnification, 2009
Fig. 7 Localization of FoxM1 in nontumor tissues of ESCC patients.
Immunohistochemistry was used to examine the expression and
localization of FoxM1 in nontumor tissues from ESCC patients,
which showed cytoplasmic FoxM1 expression in the proliferating
layer. Original magnification, 2009
Table 1 Correlations between cytoplasmic FoxMl expression and
various clinicopathological parameters in ESCC
Clinicopathological parameters Low
expression
High
expression
P-
value
Subgroups
Age (mean
in years)
64.3 65 0.797
Gender Female 11 6 0.502
Male 26 21
Smoking Non smoker 21 10 0.119
Smoker 16 17
Level of Tumor Upper 5 5 0.895
Middle 21 16
Lower 9 5
Double 2 1
Tumor
differentiation
Poor 10 4 0.481
Moderate 21 17
Well 6 6
R catergory R0 29 16 0.098
R1/R2 8 11
T-stage Early (T1/T2) 9 4 0.35
Advanced
(T3/T4)
28 23
N-stage N0 18 8 0.126
N1 19 19
M-stage M0 33 25 0.645
Mla/Mlb 4 2
Overall
pathological
stage
Early (Stage I/II) 19 6 0.018
Advanced
(Stage III/IV)
18 21
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advanced-stage cervical cancer. All of the above findings
supported a hypothesis that cytoplasmic FoxM1 might play
a role in the progression of ESCC.
Expression of nuclear FoxM1 significantly correlates
with the age of ESCC patients, i.e., patients with nuclear
FoxM1 are younger than those without nuclear FoxM1. Ly
et al. [28] previously compared the expression levels of
various genes in fibroblasts from healthy individuals of
different ages (young, middle age, and old age) and from
patients with Hutchinson-Gilford progeria, which is a rare
genetic disease accompanied by accelerated aging. Among
the different genes, FoxM1 was always downregulated in
middle-aged, old-aged, and diseased when compared to
young individuals [28]. Nuclear FoxM1 is an active form
and regulates the expression of proliferation-related genes
like cyclins [6, 7, 29, 30], which are crucial to the cell
cycle. It is thus reasonable to find the expression of nuclear
FoxM1 in younger ESCC patients since they are likely to
have a higher rate of cell proliferation compared to the
older patients.
We have found a tendency for patients with a smoking
habit to have no expression of nuclear FoxM1. Previous
studies have demonstrated that the salivary level of epi-
dermal growth factor (EGF) was 32% lower in smokers
than in nonsmokers [31, 32]. In addition, phosphorylation
of EGF receptor in the buccal cavity was impaired in
smokers as well [32]. Since the EGF receptor is involved in
the mitogen-activated protein kinase (MAPK) pathway
[33], this in turn activates FoxM1 [34]. Therefore, smok-
ing-induced reduced salivary EGF level and deficiency in
EGF receptor phosphorylation likely inhibit the activation
of FoxM1 in esophageal epithelial cells of ESCC patients
Table 2 Correlations between nuclear FoxMl expression and various
clinicopathological parameters in ESCC
Clinicopathological parameters Absence Presence P-value
Subgroups
Age (mean
in years)
67.13 57 \0.001
Gender Female 13 4 0.87
Male 35 12
Smoking Non smoker 20 11 0.06
Smoker 28 5
Level of Tumor Upper 9 1 0.371
Middle 27 10
Lower 9 5
Double 3 0
Tumor
differentiation
Poor 11 3 0.937
Moderate 28 10
Well 9 3
R catergory R0 34 11 0.874
R1/R2 14 5
T-stage Early (T1/T2) 9 4 0.59
Advanced
(T3/T4)
39 12
N-stage N0 19 7 0.769
Nl 29 9
M-stage M0 44 14 0.62
Mla/Mlb 4 2
Overall
pathological
stage
Early
(Stage I/II)
18 7 0.657
Advanced
(Stage IMV)
30 9
Fig. 8 Kaplan-Meier survival curves for cytoplasmic FoxM1. Kap-
lan-Meier survival curves were constructed for patients having high
(n = 27) or low (n = 37) expression of cytoplasmic FoxM1. Log-
rank test, P = 0.977
Fig. 9 Kaplan-Meier survival curves for nuclear FoxM1. Kaplan-
Meier survival curves were generated for patients based on the
presence (n = 16) or absence (n = 48) of nuclear FoxM1. Log-rank
test, P = 0.697
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who smoke. This might finally translate into a significant
association between smoking and the absence of nuclear
FoxM1 in ESCC patients.
HKESC-3 cells have the highest mRNA level but lowest
protein level of FoxM1 when compared to the other studied
ESCC cell lines. This could be the result of the presence of
post-translation modifications in the FoxM1 gene in ESCC.
A review from Calnan and Brunet [35] stated the presence of
a wide range of post-translation modifications such as
phosphorylation, acetylation, and ubiquitination in the FoxO
gene, which is also a member of the Forkhead transcription
factor as is FoxM1. Thus, it is possible that a similar post-
translation modification would occur in other members of the
Forkhead transcription factor family like FoxM1.
In summary, we have shown that a low cytoplasmic
FoxM1 level is correlated with early-stage ESCC and that
nuclear FoxM1 expression was found in young ESCC
patients. Therefore, FoxM1 is a potential biomarker for
late-stage ESCC.
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